Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection (‘CDI’), has appointed Dr David Roblin as Chief Medical Officer, Anne Heatherington, PhD, as Head of Clinical Development and Quantitative Sciences and Dave Powell, PhD, as Head of Research.
Dr Roblin, who recently became Chief Operating Officer and President of R&D, will expand his role to become Chief Medical Officer as he assumes full operational leadership for Summit’s R&D capability. He will replace Dr Ralf Rosskamp, who has resigned.
“This strengthening of our research and development team will help to ensure the organisation has the leadership, depth of knowledge and expertise needed to support ezutromid and ridinilazole as they enter crucial stages in their clinical evaluation and support progression of our earlier stage utrophin development pipeline,” commented Glyn Edwards, Chief Executive Officer of Summit.
Dr David Roblin said, “In the coming 12 months, Summit has the potential to achieve proof of concept with ezutromid in the treatment of DMD and plans to begin Phase 3 trials for ridinilazole in CDI, each step potentially bringing us closer to making a difference for patients and families living with these serious diseases.”
Dr Heatherington joined Summit from Pfizer and has already taken up her role in the company’s office in Cambridge, Massachusetts, US, while Dr Powell will join Summit in late June from GlaxoSmithKline (‘GSK’) and will be based at the Company’s headquarters in Oxfordshire, UK.